285 related articles for article (PubMed ID: 24951423)
1. Hemostatic disorders in a JAK2V617F-driven mouse model of myeloproliferative neoplasm.
Lamrani L; Lacout C; Ollivier V; Denis CV; Gardiner E; Ho Tin Noe B; Vainchenker W; Villeval JL; Jandrot-Perrus M
Blood; 2014 Aug; 124(7):1136-45. PubMed ID: 24951423
[TBL] [Abstract][Full Text] [Related]
2. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
3. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice.
Marty C; Lacout C; Martin A; Hasan S; Jacquot S; Birling MC; Vainchenker W; Villeval JL
Blood; 2010 Aug; 116(5):783-7. PubMed ID: 20472827
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
7. Platelet Dysfunction and Thrombosis in JAK2
Matsuura S; Thompson CR; Belghasem ME; Bekendam RH; Piasecki A; Leiva O; Ray A; Italiano J; Yang M; Merill-Skoloff G; Chitalia VC; Flaumenhaft R; Ravid K
Arterioscler Thromb Vasc Biol; 2020 Oct; 40(10):e262-e272. PubMed ID: 32814440
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis among 1537 patients with JAK2
Zhang Y; Zhou Y; Wang Y; Teng G; Li D; Wang Y; Du C; Chen Y; Zhang H; Li Y; Fu L; Chen K; Bai J
Cancer Med; 2020 Mar; 9(6):2096-2105. PubMed ID: 31994332
[TBL] [Abstract][Full Text] [Related]
9. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
10. Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.
Ha JS; Kim YK; Jung SI; Jung HR; Chung IS
Ann Lab Med; 2012 Nov; 32(6):385-91. PubMed ID: 23130336
[TBL] [Abstract][Full Text] [Related]
11. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
Michiels JJ; Berneman Z; Schroyens W; De Raeve H
Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
[TBL] [Abstract][Full Text] [Related]
12. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
[TBL] [Abstract][Full Text] [Related]
13. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
[TBL] [Abstract][Full Text] [Related]
14. Dkk3 levels in patients with myeloproliferative neoplasms.
Medinger M; Muesser P; Girsberger S; Skoda R; Tzankov A; Buser A; Passweg J; Tsakiris DΑ
Thromb Res; 2014 Feb; 133(2):218-21. PubMed ID: 24309205
[TBL] [Abstract][Full Text] [Related]
15. [Myeloproliferative diseases caused by JAK2 mutation].
Nagata K; Shimoda K
Rinsho Byori; 2009 Apr; 57(4):357-64. PubMed ID: 19489438
[TBL] [Abstract][Full Text] [Related]
16. The first international meeting on V617F JAK2 mutation and its relevance in Philadelphia-negative myeloproliferative disorders.
Kiladjian JJ; Casadevall N; Vainchenker W; Fenaux P
Pathol Biol (Paris); 2007 Mar; 55(2):85-7. PubMed ID: 16901656
[TBL] [Abstract][Full Text] [Related]
17. JAK2 exon 12 mutations in cases with JAK2V617F-negative polycythemia vera and primary myelofibrosis.
Maddali M; Kulkarni UP; Ravindra N; Jajodia E; Arunachalam AK; Suresh H; Venkatraman A; George B; Mathews V; Balasubramanian P
Ann Hematol; 2020 May; 99(5):983-989. PubMed ID: 32277273
[TBL] [Abstract][Full Text] [Related]
18. SRSF2 mutation reduces polycythemia and impairs hematopoietic progenitor functions in JAK2V617F-driven myeloproliferative neoplasm.
Yang Y; Abbas S; Sayem MA; Dutta A; Mohi G
Blood Cancer J; 2023 Nov; 13(1):171. PubMed ID: 38012156
[TBL] [Abstract][Full Text] [Related]
19. JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms.
Takahashi K; Patel KP; Kantarjian H; Luthra R; Pierce S; Cortes J; Verstovsek S
Blood; 2013 Nov; 122(23):3784-6. PubMed ID: 24068492
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of risk factors for thromboembolism in patients with JAK2
Zhang YH; Teng GS; Ma JY; Hu X; Du CX; Wang Y; Hu NB; Li YQ; Shao ZH; Bai J
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3652-3657. PubMed ID: 38018064
[No Abstract] [Full Text] [Related]
[Next] [New Search]
